TELESTA THERAPEUTICS INC T.TST

RE:Results

[sloppytrader]

DragonDoji wrote:

Results

A total of 129 patients were enrolled in study, including 91 with carcinoma in situ with or without papillary disease and 38 with papillary only tumors. Most patients had high risk disease. A total of 107 cases were bacillus Calmette-Gurin refractory and 2 or more prior bacillus Calmette-Gurin induction courses had been given in 68. Median followup in all patients was 34.7 months. The overall disease-free survival rate was 25.0% at 1 year and 19.0% at 2 years. In patients with papillary only tumors the disease-free survival rate was 35.1% and 32.2% at 1 and 2 years, respectively. The median disease-free duration in the 30 responders was 32.7 months. The progression-free survival rate was 87.3%, 79.8% and 77.7% at 1, 2 and 3 years, respectively, with a progression event in 28 patients. MCNA was well tolerated and few adverse events led to treatment discontinuation.

So 38 out of 129 patients were papillary only.   This is 29% of those cancers although not sure if this sample group was representative of overall cancer rates.  For this group, the 1 and 2 year survival rates were 35% and 32%.  Seeing how this treatment was safe and well tolerated, it would seem like this treatment should get approval at some point.

Will be interesting to see how this develops over the next few weeks/months.

DD

I LIKE THE ODDS! BETTER THAN NOTHING I WOULD THINK.